Peptide · Fact sheet

Selank

Also known as Selank acetate · TP-7

Selank is a synthetic seven-amino-acid peptide studied mainly in Russia for anxiety-related outcomes. It is not FDA approved for anxiety, cognition, focus, stress, or any other use.

Not FDA approvedLimited or unclear evidence

What is Selank?

Selank is derived from a short sequence related to the immune peptide tuftsin and has been explored for effects on anxiety and brain signaling.

Mechanistic papers describe possible effects on neurotransmitter and gene-expression pathways, but mechanism is not clinical proof.

Benefits & claims

Online nootropic communities promote it for calmness, focus, learning, and stress without the sedation associated with some anxiety medicines.

The published clinical literature is small and difficult to evaluate against current standards, and FDA says important human safety information is lacking.

What the evidence supports

  • A small randomized study reported anxiety-related outcomes, but limited accessible detail and replication constrain confidence.
  • Laboratory and animal work offers mechanistic hypotheses, not evidence of a dependable nootropic effect in people.
Research areas
  • Anxiety disorders
  • Stress and emotional regulation
  • Cognitive and memory claims
  • Neurotransmitter and immune signaling
  • Anxiety-related symptoms
  • Cognitive and stress-response outcomes

Dosage & frequency

No established human regimen

Reviewed evidence does not establish an FDA-approved Selank dose or a broadly validated anxiety-treatment schedule.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Intranasal research does not establish equivalence for other routes or formulations.

Interactions & precautions

  • A reproducible human medicine-interaction profile is not established for the intranasal preparations described in the research.

What is still unresolved

  • High-quality clinical efficacy, repeated-use safety, interactions, and reproducible exposure remain uncertain.

Side effects & risks

  • FDA identifies potential immune reactions and risks related to aggregation or peptide impurities.
  • Human safety data are too limited to define reliable adverse-event rates or long-term risks.
  • Unapproved products add quality, identity, strength, sterility, and labeling uncertainty.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

A small randomized Russian-language study and mechanistic literature exist, but there is no broad, independently replicated evidence base establishing effectiveness for anxiety or cognitive enhancement.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Sleep: reported experiences

Negative account · personal report

No anxiety relief and disrupted sleep

An author described no anxiety benefit from Selank and insomnia even when it was used earlier in the day.

Reported use in this account

Product
Product labeled Selank
Amount
Around 600 mcg without anxiety relief; sleep problems also reported at 200 mcg
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Not specified clearly

Other exposures described: Agomelatine; Low-dose bupropion; Saffron

The author described anxiety and depression, ongoing agomelatine and bupropion, and several lifestyle and supplement changes. The post asks about Semax, but the reported exposure here was Selank.

Read the original account
Mixed account · personal report

Less anxiety and better sleep after an uncomfortable first exposure

A poster described less emotional reactivity and more restorative sleep over ten days, following an initial episode of chest tightness, a faster heart rate and stomach discomfort.

Reported use in this account

Product
Product labeled Selank
Amount
375 mcg per use; 750 mcg per day as reported
Frequency
Twice daily, morning and midday
Route
Intranasal
Duration
Ten days at the time of the post

This is an uncontrolled account involving a product whose identity and strength are unverified. The author's explanation for the initial symptoms is not a clinical assessment, and the planned longer exposure was not complete at the time of the post.

Read the original account

Approval status

Selank has no FDA-approved drug product or use. FDA's current compounding safety summary states that important human safety information is lacking and describes peptide-quality and immune-reaction concerns.

No active FDA approval path identified

Selank is not FDA approved. Limited human and mechanistic research does not establish an active FDA drug-development program or an approved anxiety treatment.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether anxiety or cognition findings replicate in larger independent trials
  • Long-term neurologic, immune, and reproductive safety
  • How outcomes compare with established anxiety treatments
  • Whether marketed products contain the claimed peptide consistently

Summary

Selank is unapproved, with limited human anxiety research and substantial safety uncertainties.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

  2. pubmedRandomized study of Selank in anxiety disorders

    Small Russian-language randomized trial with limited accessible reporting and generalizability.

  3. pubmedReview of Selank biological mechanisms

    Mechanistic review that does not substitute for confirmatory clinical trials.

  4. fdaFDA: understanding the risks of compounded drugs

    FDA overview explaining that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality.

How we assess sources · Suggest a correction